300199 翰宇药业
已收盘 04-30 15:00:00
资讯
新帖
简况
翰宇药业(300199)4月26日主力资金净卖出1.90亿元
证券之星 · 04-29
翰宇药业(300199)4月26日主力资金净卖出1.90亿元
三生制药董事长娄竞率团队莅临翰宇药业
翰宇药业官微 · 04-29
三生制药董事长娄竞率团队莅临翰宇药业
图解翰宇药业年报:第四季度单季净利润同比减48.96%
证券之星 · 04-27
图解翰宇药业年报:第四季度单季净利润同比减48.96%
翰宇药业(300199.SZ)发布一季度业绩,由盈转亏至1410.2万元
智通财经 · 04-27
翰宇药业(300199.SZ)发布一季度业绩,由盈转亏至1410.2万元
翰宇药业(300199)4月22日主力资金净买入5245.29万元
证券之星 · 04-23
翰宇药业(300199)4月22日主力资金净买入5245.29万元
翰宇药业扣非连亏6年研发投入下降 曾氏兄弟五轮转让加减持套现21亿
市场资讯 · 03-13
翰宇药业扣非连亏6年研发投入下降 曾氏兄弟五轮转让加减持套现21亿
10天狂揽29亿票房!热辣滚烫火出“贾玲概念股”,减肥药、健身概念齐上阵
格隆汇 · 02-19
10天狂揽29亿票房!热辣滚烫火出“贾玲概念股”,减肥药、健身概念齐上阵
翰宇药业(300199.SZ):司美格鲁肽注射液新适应症临床试验申请获受理
智通财经网 · 02-01
翰宇药业(300199.SZ):司美格鲁肽注射液新适应症临床试验申请获受理
翰宇药业:龙华总部研发实验室通过FDA的现场检查
财华社 · 2023-12-14
翰宇药业:龙华总部研发实验室通过FDA的现场检查
翰宇药业:公司各生产基地陆续获得美国FDA认可
财华社 · 2023-11-21
翰宇药业:公司各生产基地陆续获得美国FDA认可
亿元大单!翰宇药业减肥药出海,“神秘买家”是谁?
金融界网站 · 2023-11-08
亿元大单!翰宇药业减肥药出海,“神秘买家”是谁?
翰宇药业两月签3亿出海大单股价涨60% 负债率升至65%近六年扣非亏28.55亿
市场资讯 · 2023-11-07
翰宇药业两月签3亿出海大单股价涨60% 负债率升至65%近六年扣非亏28.55亿
暂无数据
公司概况
公司名称:
深圳翰宇药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-04-07
主营业务:
深圳翰宇药业股份有限公司是一家专业从事多肽药物研发、生产和销售的国家级高新技术企业,公司主营产品包括特色原料药、制剂、客户定制肽、固体制剂、药品组合包装类产品和医疗器械产品六大系列。公司的主要制剂产品包括注射用胸腺五肽、注射用胸腺法新、注射用生长抑素、注射用特利加压素、注射用西曲瑞克、去氨加压素注射液、依替巴肽注射液、阿托西班注射液。公司的主要原料药包括特利加压素、依替巴肽、奥曲肽、卡贝缩宫素、缩宫素溶液、去氨加压素、鲑降钙素、生长抑素、曲普瑞林、胸腺五肽、胸腺法新原料药等。
发行价格:
30.19
{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":12.88,"timestamp":1714460616000,"preClose":12.23,"halted":0,"volume":64577616,"delay":0,"floatShares":666000000,"shares":883000000,"eps":-0.6189,"marketStatus":"已收盘","marketStatusCode":5,"change":0.65,"latestTime":"04-30 15:00:00","open":12.17,"high":12.96,"low":12.05,"amount":811000000,"amplitude":0.0744,"askPrice":12.88,"askSize":2448,"bidPrice":12.87,"bidSize":1963,"shortable":0,"etf":0,"ttmEps":-0.6189,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"adjPreClose":12.23,"symbolType":"stock","openAndCloseTimeList":[[1714440600000,1714447800000],[1714453200000,1714460400000]],"highLimit":13.45,"lowLimit":11.01,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"pbRate":14.44,"roa":"--","roe":"--","epsLYR":-0.58,"committee":-0.300537,"marketValue":11376000000,"floatMarketCap":8579000000,"peRate":-20.811116,"changeRate":0.0531,"turnoverRate":0.097,"status":0},"requestUrl":"/m/hq/s/300199/tweets","defaultTab":"tweets","newsList":[{"id":"2431304671","title":"翰宇药业(300199)4月26日主力资金净卖出1.90亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431304671","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431304671?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:19","pubTimestamp":1714353559,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年4月26日收盘,翰宇药业报收于12.16元,下跌6.03%,换手率11.06%,成交量73.64万手,成交额9.15亿元。近5日资金流向一览见下表:翰宇药业融资融券信息显示,融资方面,当日融资买入8847.77万元,融资偿还1.24亿元,融资净偿还3592.44万元。翰宇药业主营业务:特色原料药、注射剂、客户定制肽、固体制剂、药品组合包装类产品和医疗器械产品六大系列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900002360.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431401151","title":"三生制药董事长娄竞率团队莅临翰宇药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2431401151","media":"翰宇药业官微","top":-1,"share":"https://www.laohu8.com/m/news/2431401151?lang=zh_cn&edition=full","pubTime":"2024-04-29 06:44","pubTimestamp":1714344255,"startTime":"0","endTime":"0","summary":"4月28日,三生制药、三生国健董事长娄竞率团队莅临翰宇药业参观考察,与公司领导开展座谈交流,围绕双方在药品线上营销渠道开拓、品牌建设、以及产品规划等潜在合作方向展开交流与研讨。出 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20240429/c657383072.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430278654","title":"图解翰宇药业年报:第四季度单季净利润同比减48.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430278654","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430278654?lang=zh_cn&edition=full","pubTime":"2024-04-27 01:05","pubTimestamp":1714151108,"startTime":"0","endTime":"0","summary":"证券之星消息,翰宇药业2023年年报显示,公司主营收入4.31亿元,同比下降38.75%;归母净利润-5.14亿元,同比下降38.68%;扣非净利润-5.91亿元,同比下降87.88%;其中2023年第四季度,公司单季度主营收入2982.89万元,同比下降82.79%;单季度归母净利润-3.33亿元,同比下降48.96%;单季度扣非净利润-3.55亿元,同比下降70.14%;负债率76.1%,投资收益-978.57万元,财务费用1.25亿元,毛利率49.31%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042700001868.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430623788","title":"翰宇药业(300199.SZ)发布一季度业绩,由盈转亏至1410.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430623788","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430623788?lang=zh_cn&edition=full","pubTime":"2024-04-27 00:29","pubTimestamp":1714148981,"startTime":"0","endTime":"0","summary":"智通财经APP讯,翰宇药业(300199.SZ)发布2024年第一季度报告,该公司营业收入为1.5亿元,同比减少14.73%。归属于上市公司股东的净亏损为1410.2万元。归属于上市公司股东的扣除非经常性损益的净亏损为1607.49万元,同比收窄34.90%。基本每股亏损为0.02元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112894.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429918112","title":"翰宇药业(300199)4月22日主力资金净买入5245.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429918112","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429918112?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:11","pubTimestamp":1713834700,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年4月22日收盘,翰宇药业报收于12.04元,上涨6.64%,换手率7.25%,成交量48.27万手,成交额5.8亿元。近5日资金流向一览见下表:翰宇药业融资融券信息显示,融资方面,当日融资买入5277.32万元,融资偿还3993.06万元,融资净买入1284.26万元,连续3日净买入累计1913.98万元。翰宇药业主营业务:特色原料药、注射剂、客户定制肽、固体制剂、药品组合包装类产品和医疗器械产品六大系列。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300015892.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2419511941","title":"翰宇药业扣非连亏6年研发投入下降 曾氏兄弟五轮转让加减持套现21亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2419511941","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2419511941?lang=zh_cn&edition=full","pubTime":"2024-03-13 08:42","pubTimestamp":1710290520,"startTime":"0","endTime":"0","summary":" 来源 长江商报。 曾氏兄弟以股抵债,持股比再度下降。 3月6日晚间,翰宇药业披露,公司控股股东、实际控制人曾少贵、曾少强兄弟与深圳市高新投集团有限公司签署协议,将合计持有的公司3260.48万股股份通过非交易过户方式转让给后者。 翰宇药业称,本次股权转让,属于解决历史遗留债务问题。 综上,曾少贵三兄弟通过五轮转让,加上二级市场上减持,共计套现21.30亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/s/2024-03-13/doc-inancqsu2038870.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-03-13/doc-inancqsu2038870.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2412490529","title":"10天狂揽29亿票房!热辣滚烫火出“贾玲概念股”,减肥药、健身概念齐上阵","url":"https://stock-news.laohu8.com/highlight/detail?id=2412490529","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2412490529?lang=zh_cn&edition=full","pubTime":"2024-02-19 15:52","pubTimestamp":1708329177,"startTime":"0","endTime":"0","summary":" 新年的第一份热血来自贾玲!","market":"us","thumbnail":"https://img3.gelonghui.com/1e89b-c9590e1b-acd8-44e7-8cd5-9e4aa09f0411.jpg?guru_height=808&guru_width=1620","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/1e89b-c9590e1b-acd8-44e7-8cd5-9e4aa09f0411.jpg?guru_height=808&guru_width=1620"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/694229","is_publish_highlight":false,"gpt_icon":0},{"id":"2408689382","title":"翰宇药业(300199.SZ):司美格鲁肽注射液新适应症临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2408689382","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2408689382?lang=zh_cn&edition=full","pubTime":"2024-02-01 19:55","pubTimestamp":1706788500,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告,公司收到国家药品监督管理局核准签发关于司美格鲁肽注射液临床试验申请的《受理通知书》。相关适应症为:作为低热量饮食和增加体力活动的辅助治疗,用于肥胖,或超重且伴有至少1种体重相关合并症的成人患者体重管理。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-01/doc-inafpwqu0343391.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-01/doc-inafpwqu0343391.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2391528333","title":"翰宇药业:龙华总部研发实验室通过FDA的现场检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2391528333","media":"财华社","top":-1,"share":"https://www.laohu8.com/m/news/2391528333?lang=zh_cn&edition=full","pubTime":"2023-12-14 14:58","pubTimestamp":1702537136,"startTime":"0","endTime":"0","summary":"12月14日,翰宇药业(300199.SZ)在互动平台表示,公司于12月13日收到了美国FDA针对翰宇药业龙华总部研发实验室的现场检查报告(EIR),报告显示研发实验室质量管理体系符合美国FDA cGMP的要求,意味着研发实验室通过了FDA的现场检查。截至今日,翰宇药业多肽制剂生产基地坪山分公司、原料药生产基地武汉子公司、龙华总部研发实验室均已全部取得FDA的现场检查报告(EIR),其中研发实验室以NAI(No Action Indicated 无需采取整改)零缺陷通过。","market":"other","thumbnail":"https://www.finet.hk/images/news_default.jpg","type":0,"news_type":0,"thumbnails":["https://www.finet.hk/images/news_default.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/657aa7b053243c32aa6fe17f","is_publish_highlight":false,"gpt_icon":0},{"id":"2385751275","title":"翰宇药业:公司各生产基地陆续获得美国FDA认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2385751275","media":"财华社","top":-1,"share":"https://www.laohu8.com/m/news/2385751275?lang=zh_cn&edition=full","pubTime":"2023-11-21 14:37","pubTimestamp":1700548669,"startTime":"0","endTime":"0","summary":"11月21日,翰宇药业(300199.SZ)在互动平台表示,公司已完成坪山制剂生产基地、武汉原料药生产基地、龙华总部实验室的现场检查。其中坪山分公司取得了FDA的现场检查报告(EIR),龙华总部获得NAI(零缺陷,不需要采取任何行动)优异检查结果。公司各生产基地陆续获得美国FDA认可,将为未来产品审批通过提供坚实基础,有利于加快推进公司已申报美国ANDA产品的审批进度。坪山生产基地现有及规划多肽药品包括:利拉鲁肽、司美格鲁肽、替尔泊肽、阿巴帕肽等20余个产品;武汉生产基地现有及规划多肽原料药包括:利拉鲁肽、司美格鲁肽、格拉替雷等35个产品。","market":"hk","thumbnail":"https://www.finet.hk/images/news_default.jpg","type":0,"news_type":0,"thumbnails":["https://www.finet.hk/images/news_default.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/655c503d53243c32aa6fdef4","is_publish_highlight":false,"gpt_icon":0},{"id":"2381217254","title":"亿元大单!翰宇药业减肥药出海,“神秘买家”是谁?","url":"https://stock-news.laohu8.com/highlight/detail?id=2381217254","media":"金融界网站","top":-1,"share":"https://www.laohu8.com/m/news/2381217254?lang=zh_cn&edition=full","pubTime":"2023-11-08 12:15","pubTimestamp":1699416900,"startTime":"0","endTime":"0","summary":"对于合作方,翰宇药业只表示“为美国某大型制药公司”。翰宇药业9月公告称与海外客户签订2.19亿元GLP-1多肽原料药合同,成为中国首批获得多肽原料药出口合同的医药企业。值得注意的是,本次翰宇药业达成合作的为制剂。翰宇药业表示,上述金额仅为前端交易金额,最终以市场实际销售金额按双方约定进行后端分成,订单约定产品供应量。同时,二者签订排它协议,由翰宇药业向合作方独家供应产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2023-11-08/doc-imztwqvq1367058.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2023-11-08/doc-imztwqvq1367058.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2381384494","title":"翰宇药业两月签3亿出海大单股价涨60% 负债率升至65%近六年扣非亏28.55亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2381384494","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2381384494?lang=zh_cn&edition=full","pubTime":"2023-11-07 08:20","pubTimestamp":1699316400,"startTime":"0","endTime":"0","summary":" 11月3日晚间,翰宇药业发布公告称,近日收到美国某大型制药公司的采购订单,其向公司合计采购累计金额1408.32万美元的利拉鲁肽注射液(仿制药)。 受到上述合同的影响,翰宇药业的股价在9月20日之后大幅上涨,截至11月3日收盘,不到两个月时间,股价涨幅达60.89%。与此同时,翰宇药业的资产负债率持续攀升,截至2023年9月末,公司的负债率达65.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2023-11-07/doc-imzttzhy6708888.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2023-11-07/doc-imzttzhy6708888.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","stockEarnings":[{"period":"1week","weight":0.0531},{"period":"1month","weight":0.0583},{"period":"3month","weight":0.3063},{"period":"6month","weight":-0.2074},{"period":"1year","weight":0.119},{"period":"ytd","weight":-0.0515}],"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","perCapita":"9231股","boardName":"医药制造业","registeredCapital":"88324万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":" 深圳翰宇药业股份有限公司是一家专业从事多肽药物研发、生产和销售的国家级高新技术企业,公司主营产品包括特色原料药、制剂、客户定制肽、固体制剂、药品组合包装类产品和医疗器械产品六大系列。公司的主要制剂产品包括注射用胸腺五肽、注射用胸腺法新、注射用生长抑素、注射用特利加压素、注射用西曲瑞克、去氨加压素注射液、依替巴肽注射液、阿托西班注射液。公司的主要原料药包括特利加压素、依替巴肽、奥曲肽、卡贝缩宫素、缩宫素溶液、去氨加压素、鲑降钙素、生长抑素、曲普瑞林、胸腺五肽、胸腺法新原料药等。","serverTime":1714726158039,"listedPrice":30.19,"stockholders":"72151人(较上一季度减少4.89%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}